Glen Eagle Advisors’s West Pharmaceutical WST Stock Holding History

Glen Eagle Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.6K	Buy	113 +3	+3%	+$917	0.01%	495
2026 Q1	$27.6K	Hold	110	–	–	﹤0.01%	527
2025 Q4	$30.3K	Hold	110	–	–	﹤0.01%	526
2025 Q3	$28.9K	Hold	110	–	–	﹤0.01%	533
2025 Q2	$24.1K	Hold	110	–	–	﹤0.01%	525
2025 Q1	$24.6K	Hold	110	–	–	﹤0.01%	519
2024 Q4	$36K	Hold	110	–	–	0.01%	471
2024 Q3	$33K	Hold	110	–	–	0.01%	494
2024 Q2	$36.2K	Hold	110	–	–	0.01%	458
2024 Q1	$43.5K	Hold	110	–	–	0.01%	429
2023 Q4	$38.7K	Hold	110	–	–	0.01%	425
2023 Q3	$41.3K	Hold	110	–	–	0.01%	405
2023 Q2	$42.1K	Hold	110	–	–	0.01%	397
2023 Q1	$38.1K	Hold	110	–	–	0.01%	406
2022 Q4	$25.9K	Hold	110	–	–	0.01%	458
2022 Q3	$27.1K	Hold	110	–	–	0.01%	437
2022 Q2	$33.3K	Hold	110	–	–	0.01%	424
2022 Q1	$45.2K	Hold	110	–	–	0.01%	386
2021 Q4	$51.6K	Hold	110	–	–	0.01%	367
2021 Q3	$46.7K	Hold	110	–	–	0.01%	389
2021 Q2	$39.5K	Hold	110	–	–	0.01%	421
2021 Q1	$31K	Hold	110	–	–	0.01%	432
2020 Q4	$31.2K	Hold	110	–	–	0.01%	407
2020 Q3	$30.2K	Buy	+110	New	+$29.1K	0.01%	381
2019 Q4	–	Sell	-48	Closed	-$6.81K	–	930
2019 Q3	$6.81K	Buy	+48	New	+$6.61K	﹤0.01%	582

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Glen Eagle Advisors's WST Position: Q2 2026 in Review

Glen Eagle Advisors increased its West Pharmaceutical (WST) stake by 2.7% in Q2 2026, buying an estimated $917 and bringing the position to 113 shares worth $40.6K. The position accounts for 0.01% of the portfolio, ranked #495.

Glen Eagle Advisors first reported a position in WST in Q3 2019 and has held it in 25 quarters since. The position peaked at $51.6K in Q4 2021. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Glen Eagle Advisors held 113 shares of West Pharmaceutical worth $40.6K as of Q2 2026.
Glen Eagle Advisors bought 3 West Pharmaceutical shares in Q2 2026, an estimated $917.
West Pharmaceutical made up 0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #495 holding.
Glen Eagle Advisors first reported a position in West Pharmaceutical in Q3 2019 and has held it in 25 quarters since.
Glen Eagle Advisors's West Pharmaceutical position peaked at $51.6K in Q4 2021.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.